FDA shares reminder of recalled Gerber teething sticks after product still seen on shelves
FDA shares reminder of recalled Gerber teething sticks after product still seen on shelves 'We sincerely apologize for any concern or inconvenience this action represents to parents, caregivers and retail customers,' Gerber said.
Show Caption
Hide Caption
Tips to help manage food recalls and prevent foodborne illnesses
About 128,000 are hospitalized and 3,000 people die each year from preventable foodborne illnesses.
Payton, USA TODAY
Well-known baby product maker Gerber Products Company issued a recall reminder in tandem with the Food and Drug Administration (FDA) on April 18 after affected products were still seen on store shelves.
The original voluntary recall was initiated on Jan. 31 after the company received complaints of choking incidents resulting in at least one known emergency room visit. Gerber discontinued the production of the impacted items.
The company chose to issue a second press release concerning the recall because it recently received reports that the recalled products were still available for sale on some retailers' shelves and online.
"We have been working with the U.S. Food & Drug Administration (FDA) on this recall and will cooperate with them fully," Gerber said in the second press release. "Again, we sincerely apologize for any concern or inconvenience this action represents to parents, caregivers and retail customers."
Here's what to know about the recall.
Which Geber products were recalled?
Gerber Snacks for Baby soothe 'n' chew Teething Sticks, Strawberry Apple, Net Wt 3.2 Oz (90g), with UPC 0 15000 04618 7, all lot codes
Gerber Snacks for Baby soothe 'n' chew Teething Sticks, Banana, Net Wt 3.2 Oz (90g), with UPC 0 15000 04608 8, all lot codes
Gerber Snacks for Baby soothe 'n' chew Teething Sticks, Banana, Net Wt 1.58 Oz (45g), with UPC 0 15000 01015 7, all lot codes
What to do if you have recalled products or see them on shelves
Consumers who previously purchased Geber Soothe N Chew Teething Stick should not give it to their children. Instead, they can return the product to the store from which they purchased it for a full refund, the company said. If you spot the recalled products still for sale, do not buy them, the company added.
For questions or support, Gerber can be contacted at 1-800-4-GERBER (1-800-443-7237).
Where were the recalled Gerber products distributed?
The teething sticks were distributed nationwide via online shops, Gerber said. They were also sent to physical retailers in Puerto Rico and the following states:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Yahoo
an hour ago
- Yahoo
Enoki Mushrooms Recalled Nationwide for Potential Listeria Contamination—Here's What to Know
If you've recently grabbed some enoki mushrooms, you'll want to check your fridge. Packages of Enoki mushrooms from Hofood99 Inc. have been recalled by the FDA due to potential contamination with Listeria. The mushrooms that were recalled were sold nationwide and packaged in green plastic. They were in a 200-gram package with a UPC Barcode 6 976532 310051 on the back label, distributed by Hofood99 Inc., 21903 56th Ave., Oakland Gardens, NY 11364. Related: Are Food Recalls Really on the Rise? A Food Microbiologist Weighs In So far, no illnesses have been reported in relation to the mushrooms, but Listeria monocytogenes is a common cause of food safety recalls. Listeria can cause high fevers, severe headache, stiffness, nausea, and diarrhea in healthy people—but infection with listeria can cause stillbirth or miscarriage in pregnant women, and deadly infections in young children, the elderly, and people with weakened immune systems. Related: How to Wash Every Type of Mushroom So They're Safe to Eat If you have the affected products, do not eat them. You can destroy the mushrooms or return them to the store for a full refund. If you have any questions, you can contact Hofood99 at 917-756-9833, between 9 a.m. and 2 p.m., Monday to Friday. Read the original article on Real Simple
Yahoo
an hour ago
- Yahoo
Illinois becomes first state to require that all insurance covers Alzheimer's treatment
SPRINGFIELD, Ill. (WCIA) — Illinois is making a major expansion in patient care and access to new treatment for Alzheimer's, thanks to a new state law taking effect in July 2025. Gov. J.B. Pritzker signed a bill that will require state health insurance to cover U.S. Food and Drug Administration (FDA) approved medicine to slow down Alzheimer's and other related diseases. SEE ALSO: New Illinois laws and tax changes set to kick in on July 1, 2025 Some Alzheimer's patients will no longer have to go through step therapy — a process where insurers require patients to try and test less expensive drugs before covering the actual medication prescribed by their doctor. The Alzheimer's Association Illinois Chapter, which has been a forefront advocate for this, called the law 'groundbreaking.' 'For people living with Alzheimer's, slowing the progression of the disease changes someone's life — not only that individual's life, but the lives of their caregivers and all those around them, family and friends,' said David Olson, Director of State Affairs at the Alzheimer's Association Illinois Chapter. This coverage will also include diagnostic testing at the doctor's request. This ensures patients can access an accurate diagnosis before even starting the treatment. In 2020, there were 230,000 seniors with Alzheimer's disease or a related dementia in the state, and according to the Illinois Department of Health, that number is expected to increase to 260,000 this year. With the rise in medical costs, insurance coverage is essential for most families. Bill creating Office of State Public Defender heads to Pritzker's desk The bill's sponsor in the House, Rep. Mary Gill (D-Chicago), said with dementia, time is always at the essence. 'When it comes to slowing Alzheimer's and other dementias, every moment counts,' Gill said. 'We can't waste time on insurance gimmicks like step therapy to save a few bucks, which is why I'm thankful for the strong advocacy and bipartisan support this legislation received.' Other private insurance plans will also begin covering FDA-approved treatment starting in 2027. 'We worked collaboratively with the insurance industry on this legislation,' Olson said. 'We were able to find and agree upon language here that expands access in a way that also isn't increasing cost to consumers.' Currently, there are two types of treatments for Alzheimer's approved by the FDA. One is Lecanemab, and the other is Donanemab. These will not end the disease, as there is currently no cure for Alzheimer's. This law makes Illinois the first state to require such treatment, and advocates said they hope other states will follow its lead. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
